{"filing":{"accession_number":"0001193125-26-270328","cik":"0001885522","ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"d943192d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526270328/d943192d8k.htm"},"events":[{"id":10923,"run_id":9583,"accession_number":"0001193125-26-270328","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.65,"summary":"The company entered into a Third Amendment to its Loan and Security Agreement, modifying material terms including extension of the interest-only period and amendment of minimum liquidity covenants. This debt restructuring creates direct financial obligations and represents a material modification to the company's capital structure.","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7366,"accession_number":"0001193125-26-270328","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.45,"reasoning":"This disclosure describes entry into a Third Amendment to an existing Loan and Security Agreement, which modifies material terms including extension of the interest-only period and amendment of minimum liquidity covenants. While Item 1.01 typically covers M\u0026A transactions, the amendment of a material debt facility with modified payment terms and covenant adjustments could be considered a material definitive agreement under Item 1.01. However, this is more accurately characterized as a covenant modification or debt restructuring rather than a traditional M\u0026A activity, creating genuine uncertainty about the best event classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7367,"accession_number":"0001193125-26-270328","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 discloses creation of a direct financial obligation and incorporates Item 1.01 by reference. Item 1.01 typically covers material acquisitions, dispositions, or changes of control. The cross-reference structure indicates a significant transaction creating financial obligations, most likely M\u0026A activity. Without the full Item 1.01 text, confidence is moderate but the materiality and Item structure strongly suggest acquisition or merger activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10924,"run_id":9583,"accession_number":"0001193125-26-270328","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.73,"summary":"The company announced failure of Phase 3 clinical trials (KOASTAL-2 and -3) for navacaprant in major depressive disorder, leading to discontinuation of the program. This represents a material setback to the company's pipeline and development strategy.","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7369,"accession_number":"0001193125-26-270328","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces failure of Phase 3 clinical trials (KOASTAL-2 and -3) for navacaprant in major depressive disorder and discontinuation of the program. This represents a material setback to the company's pipeline and development strategy that would significantly affect investor assessment of the registrant's prospects, but does not fit neatly into the predefined taxonomy categories (not a restatement, impairment charge, litigation, or other specific event type). The clinical trial failure and program discontinuation constitute a material adverse development warranting \"other_material\" classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7370,"accession_number":"0001193125-26-270328","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This Item 8.01 discloses a pipeline and business update with clinical trial results and anticipated milestones, including failure of navacaprant in the KOASTAL-2 and -3 studies (primary endpoints not met: p = 0.813 and p = 0.480, respectively) and a reduction in force with cash runway extending only to Q3 2027. While the clinical failure and restructuring are material to investors, they do not fit neatly into the specific event categories (not a restatement, going-concern, impairment, or litigation); the disclosure is best classified as a material business update combining negative trial results and operational restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10925,"run_id":9583,"accession_number":"0001193125-26-270328","anchor_item_number":"2.05","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The company implemented a 35% reduction in force with $2 million in one-time restructuring costs and $10 million in annualized savings, triggered by discontinuation of navacaprant development. The restructuring reflects a material operational adjustment to the company's cost structure and workforce.","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7368,"accession_number":"0001193125-26-270328","item_number":"2.05","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a 35% reduction in force with $2 million in one-time restructuring costs and $10 million in annualized savings, triggered by discontinuation of navacaprant development. While this is a material operational event affecting the company's cost structure and workforce, it does not fit cleanly into the more specific categories (material_impairment would apply if there were asset write-downs; ma_activity would apply if this were part of a broader acquisition or disposition). The restructuring itself is the primary disclosed event, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7366,"accession_number":"0001193125-26-270328","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.45,"reasoning":"This disclosure describes entry into a Third Amendment to an existing Loan and Security Agreement, which modifies material terms including extension of the interest-only period and amendment of minimum liquidity covenants. While Item 1.01 typically covers M\u0026A transactions, the amendment of a material debt facility with modified payment terms and covenant adjustments could be considered a material definitive agreement under Item 1.01. However, this is more accurately characterized as a covenant modification or debt restructuring rather than a traditional M\u0026A activity, creating genuine uncertainty about the best event classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15"},{"id":7367,"accession_number":"0001193125-26-270328","item_number":"2.03","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 discloses creation of a direct financial obligation and incorporates Item 1.01 by reference. Item 1.01 typically covers material acquisitions, dispositions, or changes of control. The cross-reference structure indicates a significant transaction creating financial obligations, most likely M\u0026A activity. Without the full Item 1.01 text, confidence is moderate but the materiality and Item structure strongly suggest acquisition or merger activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15"},{"id":7368,"accession_number":"0001193125-26-270328","item_number":"2.05","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a 35% reduction in force with $2 million in one-time restructuring costs and $10 million in annualized savings, triggered by discontinuation of navacaprant development. While this is a material operational event affecting the company's cost structure and workforce, it does not fit cleanly into the more specific categories (material_impairment would apply if there were asset write-downs; ma_activity would apply if this were part of a broader acquisition or disposition). The restructuring itself is the primary disclosed event, making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15"},{"id":7369,"accession_number":"0001193125-26-270328","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces failure of Phase 3 clinical trials (KOASTAL-2 and -3) for navacaprant in major depressive disorder and discontinuation of the program. This represents a material setback to the company's pipeline and development strategy that would significantly affect investor assessment of the registrant's prospects, but does not fit neatly into the predefined taxonomy categories (not a restatement, impairment charge, litigation, or other specific event type). The clinical trial failure and program discontinuation constitute a material adverse development warranting \"other_material\" classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15"},{"id":7370,"accession_number":"0001193125-26-270328","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"This Item 8.01 discloses a pipeline and business update with clinical trial results and anticipated milestones, including failure of navacaprant in the KOASTAL-2 and -3 studies (primary endpoints not met: p = 0.813 and p = 0.480, respectively) and a reduction in force with cash runway extending only to Q3 2027. While the clinical failure and restructuring are material to investors, they do not fit neatly into the specific event categories (not a restatement, going-concern, impairment, or litigation); the disclosure is best classified as a material business update combining negative trial results and operational restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:16:17.316639+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-06-15"}]}